SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The dominant conversation centers on MELANIAs steep post-launch collapse and allegations that it is a Trump-family pump-and-dump scheme with little utility, prompting widespread criticism from holders and traders. A small minority still promotes dip-buying, a rebound, or a short squeeze, but bearish skepticism clearly dominates.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Larger-than-average natural-gas storage builds, elevated production, and cooling weather forecasts are driving bearish sentiment around BOIL, with Freeport LNG maintenance limiting export demand. Traders remain divided between expectations of further weakness and a potential heat-driven short squeeze, while many warn that contango, roll costs, and leveraged decay amplify downside risk.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

UNDPs collaboration with DFINITY to explore sovereign cloud and AI infrastructureincluding pilots in several countries and Pakistan-related developmentis driving attention around ICP. Traders view the initiatives as potential institutional adoption, while skeptics note they remain pilots without confirmed revenue or broad usage and question ICPs tokenomics and weak price performance.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A bearish BMF short report criticizing SELLASs REGAL Phase 3 trial design, historical controls, dilution, and valuation drove the selloff and dominated discussion. Traders are divided between dismissing it as a self-interested short thesis and worrying that the delayed 80th-event update and pending REGAL topline results could indicate weaker outcomes; no adverse company announcement has been cited.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios completion of the first German labeling and packaging run for ANKTIVA is driving discussion about the drugs European commercial rollout and potential revenue expansion. Traders are also speculating about future UAE and Saudi approvals for broader uses such as lymphopenia, while skeptics note that those developments lack formal confirmation and point to continued short- and options-related volatility.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforces strong quarterly results, raised outlook, and expanded Anthropic partnership through Claudeforce are driving a major software-sector rerating, with traders viewing AI as a potential monetization opportunity rather than an existential threat to SaaS. Bullish sentiment and short-covering dominate, though some traders argue the move is overextended and question organic growth, buyback-driven earnings strength, and the durability of the AI thesis.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas upcoming Cybercab and robotaxi rollout is the dominant catalyst, with bulls highlighting potential growth in autonomy, robotics, and energy while skeptics point to the limited supervised deployment, competition from Waymo, and elevated valuation. The debate is amplified by heavy short-dated options activity and broader volatility surrounding Federal Reserve commentary.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canada is drawing attention after monetizing a minority stake in Aeroplan and posting better-than-expected quarterly results, with proceeds supporting debt repayment and share buybacks. Traders are largely bullish on the valuation unlock, strong travel demand and potential short covering, while skeptics remain focused on fuel costs, labor expenses and leverage.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is surging as positive Phase III data for ivonescimab in biliary tract cancer validates the drug's platform potential, while heavy insider buying from CEO Robert Duggan and other executives signals strong conviction ahead of the FDA decision.

ETF Opportunities Trust - T-Rex 2X Long MSTR Daily Target ETF

T-Rex 2X Long MSTR Daily Target ETF

A 1-for-10 reverse split has put MSTU under scrutiny, with traders debating option adjustments, liquidity and the leveraged funds ongoing decay. The broader discussion remains tied to Bitcoin and Strategy (MSTR): bulls expect a rebound if crypto rises, while bears warn that volatility, daily reset losses and repeated reverse splits could continue eroding holders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Attention is centered on the anticipated PHVS Phase 3 hereditary-angioedema data readout and its potential implications for BioCrysts Orladeyo and navenibart franchise, with traders positioning in September options and debating the competitive threat. Buyout speculation and frustration that strong operating results have not translated into sustained share-price gains are also prominent, while some traders remain concerned about dilution and low-volume trading.

BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset

Equity

CEO Gayer told CNBC in an interview that the company is now profitable and plans to use that cash to invest in other rare-disease medicines.

Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

The consensus price target hints at a 98.7% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

Investors need to pay close attention to BCRX stock based on the movements in the options market lately. 

BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation

BioCryst raised its full-year 2026 total revenue outlook to $690 million to $715 million, up from its previous estimates of $635 million to $660 million.

BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of +114.29% and +18.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biocryst Pharmaceuticals Inc Q2 Profit Climbs

(RTTNews) - Biocryst Pharmaceuticals Inc (BCRX) released earnings for its second quarter that Increased, from the same period last year...

Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower 

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.

BioCryst Pharmaceuticals Appoints David Jenkins As Chief Scientific Officer

(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX) said on Wednesday that it has appointed David W. Jenkins to the newly created role of Chief Scientific Officer with immediate effect...

Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet

The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

• Reported GAAP EPS of $0.31 up 1450.00% YoY
• Reported revenue of $218.25M up 33.61% YoY
• BioCryst Pharmaceuticals maintained its full year 2026 ORLADEYO revenue guidance of $625 million to $645 million and increased its total revenue guidance to a range of $690 million to $715 million.

BioCryst Pharmaceuticals faces structural risks from facility closures and internal program discontinuations, alongside a significant GAAP net loss for the first half of 2026 and uncertainties regarding execution of strategic plans.

BioCryst Pharmaceuticals delivered strong revenue growth and positive free cash flow, supported by the pediatric launch of ORLADEYO oral pellets and the successful completion of pivotal navenibart trial enrollment.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a positive week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

BCRX Biocryst Pharmaceuticals Inc.

Fundamentals

Connect Stocktwits to ChatGPT

Latest BCRX News